Christine A Iacobuzio-Donahue

List of Publications by Citations

300 papers	46,092 citations	97 h-index	213 g-index
338 ext. papers	54,363 ext. citations	12.2 avg, IF	6.81 L-index

#	Paper	IF	Citations
300	Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. *Science*, **2008**, 321, 1801-6	33.3	3223
299	Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. *Science*, **2009**, 324, 1457-61	33.3	2364
298	Distant metastasis occurs late during the genetic evolution of pancreatic cancer. *Nature*, **2010**, 467, 1114-7	50.4	1834
297	Genomic analyses identify molecular subtypes of pancreatic cancer. *Nature*, **2016**, 531, 47-52	50.4	1785
296	Massive genomic rearrangement acquired in a single catastrophic event during cancer development. *Cell*, **2011**, 144, 27-40	56.2	1628
295	Whole genomes redefine the mutational landscape of pancreatic cancer. *Nature*, **2015**, 518, 495-501	50.4	1579
294	A draft map of the human proteome. *Nature*, **2014**, 509, 575-81	50.4	1520
293	Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. *Nature*, **2011**, 475, 106-9	50.4	1458
292	Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. *Nature*, **2012**, 491, 399-405	50.4	1427
291	Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. *Cancer Cell*, **2014**, 25, 735-47	24.3	1235
290	Organoid models of human and mouse ductal pancreatic cancer. *Cell*, **2015**, 160, 324-38	56.2	1072
289	The patterns and dynamics of genomic instability in metastatic pancreatic cancer. *Nature*, **2010**, 467, 1109-13	50.4	1013
288	Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. *Nature Genetics*, **2015**, 47, 1168-78	36.3	893
287	DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. *Journal of Clinical Oncology*, **2009**, 27, 1806-13	2.2	793
286	Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. *Science*, **2009**, 324, 217	33.3	608
285	Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. *Cancer Research*, **2007**, 67, 2187-96	10.1	594
284	Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. *Cancer Cell*, **2003**, 3, 565-76	24.3	584

283	Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. *Nature*, **2017**, 551, 512-516	50.4	533
282	Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. *Nature*, **2010**, 464, 610-4	50.4	415
281	Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. *American Journal of Pathology*, **2003**, 162, 1151-62	5.8	397
280	Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. *Cancer Discovery*, **2018**, 8, 1112-1129	24.4	394
279	Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an "intestinal" pathway of carcinogenesis in the pancreas. *American Journal of Surgical Pathology*, **2004**, 28, 839-48	6.7	384
278	Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). *Clinical Cancer Research*, **2001**, 7, 3862-8	12.9	377
277	Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. *American Journal of Surgical Pathology*, **2012**, 36, 173-84	6.7	366
276	An in vivo platform for translational drug development in pancreatic cancer. *Clinical Cancer Research*, **2006**, 12, 4652-61	12.9	364
275	TGF-Tumor Suppression through a Lethal EMT. *Cell*, **2016**, 164, 1015-30	56.2	363
274	Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. *Journal of the National Cancer Institute*, **2010**, 102, 340-51	9.7	340
273	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. *Cancer Cell*, **2018**, 34, 427-438.e6	24.3	339
272	Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. *Nature Medicine*, **2016**, 22, 497-505	50.5	338
271	Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. *Cancer*, **2015**, 121, 1128-37	6.4	334
270	Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. *Oncotarget*, **2011**, 2, 627-37	3.3	330
269	Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. *Journal of Clinical Oncology*, **2007**, 25, 319-25	2.2	330
268	Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. *American Journal of Pathology*, **2011**, 179, 1608-15	5.8	328
267	Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. *Modern Pathology*, **2003**, 16, 902-12	9.8	317
266	Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. *Cancer Research*, **2003**, 63, 8614-22	10.1	299

265	Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies. *Cell Reports*, **2016**, 17, 2445-2459	10.6	293
264	Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. *Cell*, **2012**, 148, 362-75	56.2	292
263	SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. *Clinical Cancer Research*, **2009**, 15, 4674-9	12.9	275
262	Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. *Science*, **2005**, 307, 1976-8	33.3	272
261	Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. *Clinical Cancer Research*, **2004**, 10, 3317-26	12.9	263
260	Nuclear beta-catenin expression distinguishes deep fibromatosis from other benign and malignant fibroblastic and myofibroblastic lesions. *American Journal of Surgical Pathology*, **2005**, 29, 653-9	6.7	254
259	The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. *Nature*, **2012**, 486, 266-70	50.4	253
258	Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. *American Journal of Pathology*, **2002**, 160, 1239-49	5.8	252
257	Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis. *Nature Genetics*, **2017**, 49, 367-376	36.3	250
256	Pancreatic cancer biology and genetics from an evolutionary perspective. *Nature Reviews Cancer*, **2016**, 16, 553-65	31.3	235
255	Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity. *Annals of Surgery*, **2001**, 234, 313-21; discussion 321-2	7.8	233
254	Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. *Human Mutation*, **2012**, 33, 100-3	4.7	230
253	Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. *Nature Genetics*, **2017**, 49, 358-366	36.3	228
252	Pancreatic cancer. *Current Problems in Cancer*, **2002**, 26, 176-275	2.3	221
251	STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. *American Journal of Pathology*, **2001**, 159, 2017-22	5.8	214
250	Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. *American Journal of Pathology*, **2000**, 157, 755-61	5.8	210
249	Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. *Cancer Research*, **2003**, 63, 4158-66	10.1	210
248	Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. *Cancer Discovery*, **2016**, 6, 166-75	24.4	206

247	Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells. *Cell*, **2020**, 181, 1643-1660.e17	56.2	200
246	Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. *Clinical Cancer Research*, **2018**, 24, 1326-1336	12.9	198
245	Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. *Cancer Research*, **2009**, 69, 4691-9	10.1	182
244	Risk of colorectal cancer in juvenile polyposis. *Gut*, **2007**, 56, 965-7	19.2	181
243	Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas. *American Journal of Pathology*, **2004**, 164, 903-14	5.8	176
242	Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas. *Annals of Surgery*, **2010**, 251, 470-6	7.8	171
241	A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. *PLoS Medicine*, **2010**, 7, e1000307	11.6	163
240	Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. *Clinical Cancer Research*, **2012**, 18, 6339-47	12.9	163
239	Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 3089-94	11.5	163
238	Long interspersed element-1 protein expression is a hallmark of many human cancers. *American Journal of Pathology*, **2014**, 184, 1280-6	5.8	158
237	The pathology and genetics of metastatic pancreatic cancer. *Archives of Pathology and Laboratory Medicine*, **2009**, 133, 413-22	5	153
236	Results of pancreaticoduodenectomy for lymphoplasmacytic sclerosing pancreatitis. *Annals of Surgery*, **2003**, 237, 853-8; discussion 858-9	7.8	152
235	Exploring the host desmoplastic response to pancreatic carcinoma: gene expression of stromal and neoplastic cells at the site of primary invasion. *American Journal of Pathology*, **2002**, 160, 91-9	5.8	148
234	The mutational landscape of normal human endometrial epithelium. *Nature*, **2020**, 580, 640-646	50.4	148
233	Minimal functional driver gene heterogeneity among untreated metastases. *Science*, **2018**, 361, 1033-1037	33.3	147
232	Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 1692-1697	11.5	144
231	Sessile serrated adenomas with low- and high-grade dysplasia and early carcinomas: an immunohistochemical study of serrated lesions "caught in the act". *American Journal of Clinical Pathology*, **2006**, 126, 564-71	1.9	142
230	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. *Cell*, **2020**, 181, 236-249	56.2	140

229	Claudin 4 Protein Expression in Primary and Metastatic Pancreatic Cancer. *American Journal of Clinical Pathology*, **2004**, 121, 226-230	1.9	139
228	Dpc4 protein in mucinous cystic neoplasms of the pancreas: frequent loss of expression in invasive carcinomas suggests a role in genetic progression. *American Journal of Surgical Pathology*, **2000**, 24, 1544-8	6.7	137
227	Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. *Carcinogenesis*, **2003**, 24, 193-8	4.6	133
226	Evolution and dynamics of pancreatic cancer progression. *Oncogene*, **2013**, 32, 5253-60	9.2	131
225	Hypermutation In Pancreatic Cancer. *Gastroenterology*, **2017**, 152, 68-74.e2	13.3	130
224	Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer. *Clinical Cancer Research*, **2008**, 14, 412-8	12.9	129
223	Epigenetic changes in cancer. *Annual Review of Pathology: Mechanisms of Disease*, **2009**, 4, 229-49	34	128
222	Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. *Oncogene*, **2005**, 24, 850-8	9.2	128
221	Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. *Clinical Cancer Research*, **2006**, 12, 2492-7	12.9	127
220	Genomic and epigenomic integration identifies a prognostic signature in colon cancer. *Clinical Cancer Research*, **2011**, 17, 1535-45	12.9	125
219	Colchicine toxicity: distinct morphologic findings in gastrointestinal biopsies. *American Journal of Surgical Pathology*, **2001**, 25, 1067-73	6.7	121
218	Immunohistochemical validation of a novel epithelial and a novel stromal marker of pancreatic ductal adenocarcinoma identified by global expression microarrays: sea urchin fascin homolog and heat shock protein 47. *American Journal of Clinical Pathology*, **2002**, 118, 52-9	1.9	116
217	Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. *Cancer Biology and Therapy*, **2005**, 4, 548-54	4.6	114
216	Almost all infiltrating colloid carcinomas of the pancreas and periampullary region arise from in situ papillary neoplasms: a study of 39 cases. *American Journal of Surgical Pathology*, **2002**, 26, 56-63	6.7	114
215	Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project. *Gut*, **2012**, 61, 1085-94	19.2	110
214	Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas. *Gastroenterology*, **2002**, 123, 365-72	13.3	108
213	Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. *Clinical Cancer Research*, **2017**, 23, 6094-6100	12.9	107
212	Molecular pathology of pancreatic cancer. *Cancer Journal (Sudbury, Mass.)*, **2001**, 7, 251-8	2.2	107

211	Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. *Journal of the National Cancer Institute*, **2018**, 110, 1067-1074	9.7	103
210	Novel methylation biomarker panel for the early detection of pancreatic cancer. *Clinical Cancer Research*, **2013**, 19, 6544-6555	12.9	103
209	Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencing. *Clinical Cancer Research*, **2012**, 18, 4257-65	12.9	101
208	Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification. *Cancer Biology and Therapy*, **2008**, 7, 1793-802	4.6	101
207	AGR2 is a novel surface antigen that promotes the dissemination of pancreatic cancer cells through regulation of cathepsins B and D. *Cancer Research*, **2011**, 71, 7091-102	10.1	99
206	Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases. *Science*, **2018**, 360,	33.3	99
205	Retrotransposon insertions in the clonal evolution of pancreatic ductal adenocarcinoma. *Nature Medicine*, **2015**, 21, 1060-4	50.5	97
204	Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. *Annals of Surgery*, **2016**, 264, 1073-1081	7.8	97
203	Widespread somatic L1 retrotransposition occurs early during gastrointestinal cancer evolution. *Genome Research*, **2015**, 25, 1536-45	9.7	92
202	Downregulation of sodium transporters and NHERF proteins in IBD patients and mouse colitis models: potential contributors to IBD-associated diarrhea. *Inflammatory Bowel Diseases*, **2009**, 15, 261-74	4.5	91
201	Enhanced sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 20926-31	11.5	90
200	Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers. *Cancer Research*, **2003**, 63, 994-9	10.1	90
199	Genetic mutations associated with cigarette smoking in pancreatic cancer. *Cancer Research*, **2009**, 69, 3681-8	10.1	88
198	HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma. *Modern Pathology*, **2009**, 22, 43-9	9.8	87
197	Beta-catenin nuclear labeling is a common feature of sessile serrated adenomas and correlates with early neoplastic progression after BRAF activation. *American Journal of Surgical Pathology*, **2009**, 33, 1823-32	6.7	86
196	A Quantitative System for Studying Metastasis Using Transparent Zebrafish. *Cancer Research*, **2015**, 75, 4272-4282	10.1	85
195	p53 mutations cooperate with oncogenic Kras to promote adenocarcinoma from pancreatic ductal cells. *Oncogene*, **2016**, 35, 4282-8	9.2	85
194	Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. *Cancer Research*, **2008**, 68, 2841-9	10.1	84

193	Missense mutations of MADH4: characterization of the mutational hot spot and functional consequences in human tumors. *Clinical Cancer Research*, **2004**, 10, 1597-604	12.9	82
192	Cytomegaloviral enterocolitis: clinical associations and outcome. *Diseases of the Colon and Rectum*, **1999**, 42, 24-30	3.1	82
191	HMGA1 induces intestinal polyposis in transgenic mice and drives tumor progression and stem cell properties in colon cancer cells. *PLoS ONE*, **2012**, 7, e30034	3.7	81
190	The desmoplastic response to infiltrating breast carcinoma: gene expression at the site of primary invasion and implications for comparisons between tumor types. *Cancer Research*, **2002**, 62, 5351-7	10.1	81
189	Reconstructing metastatic seeding patterns of human cancers. *Nature Communications*, **2017**, 8, 14114	17.4	79
188	Metastatic progression is associated with dynamic changes in the local microenvironment. *Nature Communications*, **2016**, 7, 12819	17.4	79
187	and Amplifications Determine Response to HER2 Inhibition in -Amplified Esophagogastric Cancer. *Cancer Discovery*, **2019**, 9, 199-209	24.4	79
186	Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas. *Modern Pathology*, **2011**, 24, 1237-47	9.8	74
185	Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays. *Cancer Research*, **2006**, 66, 7920-8	10.1	74
184	An analysis of genetic heterogeneity in untreated cancers. *Nature Reviews Cancer*, **2019**, 19, 639-650	31.3	71
183	Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo. *Oncotarget*, **2011**, 2, 862-73	3.3	70
182	Processed pseudogenes acquired somatically during cancer development. *Nature Communications*, **2014**, 5, 3644	17.4	68
181	Unifying cancer and normal RNA sequencing data from different sources. *Scientific Data*, **2018**, 5, 180061	8.2	66
180	Integrin alpha2 mediates selective metastasis to the liver. *Cancer Research*, **2009**, 69, 7320-8	10.1	66
179	Large-scale allelotype of pancreaticobiliary carcinoma provides quantitative estimates of genome-wide allelic loss. *Cancer Research*, **2004**, 64, 871-5	10.1	66
178	Differentially expressed genes in pancreatic ductal adenocarcinomas identified through serial analysis of gene expression. *Cancer Biology and Therapy*, **2004**, 3, 1254-61	4.6	66
177	GATA6 activates Wnt signaling in pancreatic cancer by negatively regulating the Wnt antagonist Dickkopf-1. *PLoS ONE*, **2011**, 6, e22129	3.7	66
176	Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood. *Clinical Epigenetics*, **2019**, 11, 59	7.7	65

175	Molecular pathways in pancreatic carcinogenesis. *Journal of Surgical Oncology*, **2013**, 107, 8-14	2.8	62
174	HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma. *Modern Pathology*, **2010**, 23, 98-104	9.8	62
173	Claudin 4 protein expression in primary and metastatic pancreatic cancer: support for use as a therapeutic target. *American Journal of Clinical Pathology*, **2004**, 121, 226-30	1.9	62
172	Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer. *Science Signaling*, **2015**, 8, ra77	8.8	61
171	Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. *British Journal of Cancer*, **2010**, 103, 649-55	8.7	61
170	Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: a potential new target for therapy. *Cancer Biology and Therapy*, **2005**, 4, 83-6	4.6	59
169	MAP2K4/MKK4 expression in pancreatic cancer: genetic validation of immunohistochemistry and relationship to disease course. *Clinical Cancer Research*, **2004**, 10, 8516-20	12.9	58
168	Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection. *Clinical Cancer Research*, **2020**, 26, 3239-3247	12.9	58
167	Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor-vessel relationships. *Journal of Radiation Oncology*, **2013**, 2, 413-425	0.7	57
166	Clinicopathologic and genetic characterization of traditional serrated adenomas of the colon. *American Journal of Clinical Pathology*, **2012**, 138, 356-66	1.9	57
165	A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma.. *Nature Cancer*, **2020**, 1, 59-74	15.4	56
164	Cancer cells deploy lipocalin-2 to collect limiting iron in leptomeningeal metastasis. *Science*, **2020**, 369, 276-282	33.3	56
163	Frequent genomic copy number gain and overexpression of GATA-6 in pancreatic carcinoma. *Cancer Biology and Therapy*, **2008**, 7, 1593-601	4.6	55
162	Precancerous neoplastic cells can move through the pancreatic ductal system. *Nature*, **2018**, 561, 201-205	50.4	55
161	The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes. *Modern Pathology*, **2016**, 29, 1058-69	9.8	54
160	Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G -> C COX-2 polymorphism. *Clinical Cancer Research*, **2005**, 11, 4090-6	12.9	54
159	Efficacy and Safety of Curcumin in Treatment of Intestinal Adenomas in Patients With Familial Adenomatous Polyposis. *Gastroenterology*, **2018**, 155, 668-673	13.3	53
158	Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy. *Clinical Cancer Research*, **2017**, 23, 3168-3180	12.9	51

157	Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity. *Clinical Cancer Research*, **2012**, 18, 6519-30	12.9	51
156	DNA methylation biomarker candidates for early detection of colon cancer. *Tumor Biology*, **2012**, 33, 363-72	2.9	49
155	High cancer-specific expression of mesothelin (MSLN) is attributable to an upstream enhancer containing a transcription enhancer factor dependent MCAT motif. *Cancer Research*, **2007**, 67, 9055-65	10.1	49
154	Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status. *Clinical and Experimental Metastasis*, **2006**, 23, 357-65	4.7	44
153	Heterogeneity of pancreatic cancer metastases in a single patient revealed by quantitative proteomics. *Molecular and Cellular Proteomics*, **2014**, 13, 2803-11	7.6	43
152	Occurrence of colorectal adenomas in younger adults: an epidemiologic necropsy study. *Clinical Gastroenterology and Hepatology*, **2008**, 6, 1011-5	6.9	43
151	Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2016**, 469, 523-532	5.1	42
150	Sessile serrated adenomas and classical adenomas: an epigenetic perspective on premalignant neoplastic lesions of the gastrointestinal tract. *International Journal of Cancer*, **2011**, 129, 1889-98	7.5	41
149	CpG island methylator phenotype-positive tumors in the absence of MLH1 methylation constitute a distinct subset of duodenal adenocarcinomas and are associated with poor prognosis. *Clinical Cancer Research*, **2012**, 18, 4743-52	12.9	41
148	Elevations in cathepsin B protein content and enzyme activity occur independently of glycosylation during colorectal tumor progression. *Journal of Biological Chemistry*, **1997**, 272, 29190-9	5.4	41
147	Young patients undergoing resection of pancreatic cancer fare better than their older counterparts. *Journal of Gastrointestinal Surgery*, **2013**, 17, 339-44	3.3	38
146	A broad survey of cathepsin K immunoreactivity in human neoplasms. *American Journal of Clinical Pathology*, **2013**, 139, 151-9	1.9	38
145	Frequent beta-catenin nuclear labeling in sessile serrated polyps of the colorectum with neoplastic potential. *American Journal of Clinical Pathology*, **2008**, 129, 416-23	1.9	38
144	Deep clonal profiling of formalin fixed paraffin embedded clinical samples. *PLoS ONE*, **2012**, 7, e50586	3.7	37
143	Reliable Detection of Somatic Mutations in Fine Needle Aspirates of Pancreatic Cancer With Next-generation Sequencing: Implications for Surgical Management. *Annals of Surgery*, **2016**, 263, 153-61	7.8	37
142	Aberrant methylation of Reprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma. *Cancer*, **2006**, 107, 251-7	6.4	36
141	HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. *Cell Reports*, **2020**, 31, 107625	10.6	34
140	Pancreaticobiliary cancers with deficient methylenetetrahydrofolate reductase genotypes. *Clinical Gastroenterology and Hepatology*, **2005**, 3, 752-60	6.9	34

139	ETS-Transcription Factor ETV1 Regulates Stromal Expansion and Metastasis in Pancreatic Cancer. *Gastroenterology*, **2016**, 151, 540-553.e14	13.3	34
138	The Evolutionary Origins of Recurrent Pancreatic Cancer. *Cancer Discovery*, **2020**, 10, 792-805	24.4	33
137	Autophagy, p53, and pancreatic cancer. *New England Journal of Medicine*, **2014**, 370, 1352-3	59.2	33
136	Assessment of Epidermal Growth Factor Receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis. *Cancer Biology and Therapy*, **2005**, 4, 1381-6	4.6	33
135	Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. *Gastroenterology*, **2021**, 160, 362-377.e13	13.3	32
134	The mutational landscape of human somatic and germline cells. *Nature*, **2021**, 597, 381-386	50.4	32
133	Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches. *Expert Review of Gastroenterology and Hepatology*, **2016**, 10, 893-905	4.2	31
132	Stromal responses to carcinomas of the pancreas: juxtatumoral gene expression conforms to the infiltrating pattern and not the biologic subtype. *Cancer Biology and Therapy*, **2005**, 4, 302-7	4.6	31
131	Gene expression profiling identifies markers of ampullary adenocarcinoma. *Cancer Biology and Therapy*, **2004**, 3, 651-6	4.6	31
130	Functional p38 MAPK identified by biomarker profiling of pancreatic cancer restrains growth through JNK inhibition and correlates with improved survival. *Clinical Cancer Research*, **2014**, 20, 6200-11	12.9	29
129	Patchy distribution of pathologic abnormalities in autoimmune pancreatitis: implications for preoperative diagnosis. *American Journal of Surgical Pathology*, **2008**, 32, 1762-9	6.7	29
128	dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial. *Cancer Biology and Therapy*, **2014**, 15, 688-98	4.6	28
127	Evaluation of GATA-4 and GATA-5 methylation profiles in human pancreatic cancers indicate promoter methylation patterns distinct from other human tumor types. *Cancer Biology and Therapy* , **2007**, 6, 1546-52	4.6	28
126	Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer. *Molecular Cancer Therapeutics*, **2007**, 6, 1079-88	6.1	28
125	A new branch on the tree: next-generation sequencing in the study of cancer evolution. *Seminars in Cell and Developmental Biology*, **2012**, 23, 237-42	7.5	27
124	Cancer biology as revealed by the research autopsy. *Nature Reviews Cancer*, **2019**, 19, 686-697	31.3	26
123	ID1 Mediates Escape from TGF Tumor Suppression in Pancreatic Cancer. *Cancer Discovery*, **2020**, 10, 142-157	24.4	26
122	Increased expression of cytoplasmic HuR in familial adenomatous polyposis. *Cancer Biology and Therapy*, **2008**, 7, 424-7	4.6	25

121	Reed-Sternberg-like cells in lymph node aspirates in the absence of Hodgkin's disease: pathologic significance and differential diagnosis. *Diagnostic Cytopathology*, **2002**, 27, 335-9	1.4	25
120	Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy. *Expert Opinion on Therapeutic Targets*, **2016**, 20, 341-59	6.4	24
119	Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4 and overexpression of matrix metalloproteinase 9. *Breast Cancer Research*, **2008**, 10, R91	8.3	24
118	Mutant p53 Together with TGFβ Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer. *Clinical Cancer Research*, **2017**, 23, 1607-1620	12.9	23
117	Intratumor heterogeneity reflects clinical disease course.. *Nature Cancer*, **2020**, 1, 3-6	15.4	23
116	p120 Catenin Suppresses Basal Epithelial Cell Extrusion in Invasive Pancreatic Neoplasia. *Cancer Research*, **2016**, 76, 3351-63	10.1	23
115	Cell division rates decrease with age, providing a potential explanation for the age-dependent deceleration in cancer incidence. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 20482-20488	11.5	22
114	CT radiomics associations with genotype and stromal content in pancreatic ductal adenocarcinoma. *Abdominal Radiology*, **2019**, 44, 3148-3157	3	22
113	Sessile serrated adenomas: high-risk lesions?. *Human Pathology*, **2012**, 43, 1808-14	3.7	22
112	Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays. *Molecular Cancer Therapeutics*, **2007**, 6, 515-23	6.1	22
111	RPL38, FOSL1, and UPP1 are predominantly expressed in the pancreatic ductal epithelium. *Pancreas*, **2005**, 30, 158-67	2.6	22
110	Genomic Landscape of Pancreatic Adenocarcinoma in Younger versus Older Patients: Does Age Matter?. *Clinical Cancer Research*, **2019**, 25, 2185-2193	12.9	22
109	Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients. *Cancer Cell*, **2021**, 39, 276-283.e3	24.3	22
108	Cathepsin B activity and protein levels in thyroid carcinoma, Graves' disease, and multinodular goiters. *Thyroid*, **1999**, 9, 569-77	6.2	21
107	IGFBP-3 Gene Methylation in Primary Tumor Predicts Recurrence of Stage II Colorectal Cancers. *Annals of Surgery*, **2016**, 263, 337-44	7.8	20
106	Histologic variations in juvenile polyp phenotype correlate with genetic defect underlying juvenile polyposis. *American Journal of Surgical Pathology*, **2011**, 35, 530-6	6.7	20
105	When should one subtract background fluorescence in 2-color microarrays?. *Biostatistics*, **2007**, 8, 695-707	3.7	20
104	Origin of metastases: subspecies of cancers generated by intrinsic karyotypic variations. *Cell Cycle*, **2012**, 11, 1151-66	4.7	19

103	The pancreatic cancer genome revisited. *Nature Reviews Gastroenterology and Hepatology*, **2021**, 18, 469-481	24.2	19
102	Pancreatic cancer genomics: insights and opportunities for clinical translation. *Genome Medicine*, **2013**, 5, 26	14.4	18
101	RhoC interacts with integrin 51 and enhances its trafficking in migrating pancreatic carcinoma cells. *PLoS ONE*, **2013**, 8, e81575	3.7	18
100	Pancreatic cancer: Pancreatic carcinogenesis - several small steps or one giant leap?. *Nature Reviews Gastroenterology and Hepatology*, **2016**, 14, 7-8	24.2	17
99	Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinoma. *International Journal of Radiation Oncology Biology Physics*, **2013**, 87, 458-9	4	17
98	The tumor suppressor rpl36 restrains KRAS(G12V)-induced pancreatic cancer. *Zebrafish*, **2014**, 11, 551-9	2	17
97	Establishment and characterization of a new cell line, A99, from a primary small cell carcinoma of the pancreas. *Pancreas*, **2011**, 40, 905-10	2.6	17
96	Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. *Clinical Colorectal Cancer*, **2010**, 9, 297-304	3.8	17
95	Gene expression profiles associated with advanced pancreatic cancer. *International Journal of Clinical and Experimental Pathology*, **2008**, 1, 32-43	1.4	17
94	Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer. *Practical Radiation Oncology*, **2016**, 6, 417-424	2.8	17
93	Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. *Cancer*, **2020**, 126, 3939-3949	6.4	16
92	Genetic and clinical correlates of entosis in pancreatic ductal adenocarcinoma. *Modern Pathology*, **2020**, 33, 1822-1831	9.8	16
91	Accelerated single cell seeding in relapsed multiple myeloma. *Nature Communications*, **2020**, 11, 3617	17.4	16
90	CNS involvement in pancreatic adenocarcinoma: a report of eight cases from the Johns Hopkins Hospital and review of literature. *Journal of Gastrointestinal Cancer*, **2015**, 46, 5-8	1.6	15
89	FAM190A deficiency creates a cell division defect. *American Journal of Pathology*, **2013**, 183, 296-303	5.8	15
88	Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor. *Journal of Clinical Investigation*, **2020**, 130, 6668-6676	15.9	15
87	Recurrent, truncating SOX9 mutations are associated with SOX9 overexpression, KRAS mutation, and TP53 wild type status in colorectal carcinoma. *Oncotarget*, **2016**, 7, 50875-50882	3.3	15
86	MUC1 Promoter-Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer. *Molecular Cancer Research*, **2015**, 13, 439-48	6.6	14

85	Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation. *Pancreas*, **2018**, 47, 208-212	2.6	14
84	Tumors with unmethylated MLH1 and the CpG island methylator phenotype are associated with a poor prognosis in stage II colorectal cancer patients. *Oncotarget*, **2016**, 7, 86480-86489	3.3	14
83	Rapid characterization of candidate biomarkers for pancreatic cancer using cell microarrays (CMAs). *Journal of Proteome Research*, **2012**, 11, 5556-63	5.6	13
82	Quantification of nucleic acid quality in postmortem tissues from a cancer research autopsy program. *Oncotarget*, **2016**, 7, 66906-66921	3.3	13
81	Multi-omic analysis of lung tumors defines pathways activated in neuroendocrine transformation. *Cancer Discovery*, **2021**,	24.4	13
80	KRAS G>A mutation favors poor tumor differentiation but may not be associated with prognosis in patients with curatively resected duodenal adenocarcinoma. *International Journal of Cancer*, **2013**, 132, 2502-9	7.5	12
79	Differential expression of multiple genes in association with MADH4/DPC4/SMAD4 inactivation in pancreatic cancer. *International Journal of Clinical and Experimental Pathology*, **2008**, 1, 510-7	1.4	12
78	Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review. *Pancreas*, **2021**, 50, 251-279	2.6	12
77	Hypersensitivities for acetaldehyde and other agents among cancer cells null for clinically relevant Fanconi anemia genes. *American Journal of Pathology*, **2014**, 184, 260-70	5.8	11
76	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.. *Cell*, **2022**, 185, 563-575.e11	56.2	11
75	The developmental transcription factor Gata4 is overexpressed in pancreatic ductal adenocarcinoma. *International Journal of Clinical and Experimental Pathology*, **2009**, 3, 47-55	1.4	11
74	Characterization of genetic subclonal evolution in pancreatic cancer mouse models. *Nature Communications*, **2019**, 10, 5435	17.4	11
73	Fumarate hydratase FH c.1431_1433dupAAA (p.Lys477dup) variant is not associated with cancer including renal cell carcinoma. *Human Mutation*, **2020**, 41, 103-109	4.7	11
72	iNOS Regulates the Therapeutic Response of Pancreatic Cancer Cells to Radiotherapy. *Cancer Research*, **2020**, 80, 1681-1692	10.1	11
71	Increased cyclooxygenase-2 expression in juvenile polyposis syndrome. *Clinical Gastroenterology and Hepatology*, **2009**, 7, 93-7	6.9	10
70	Gene expression in neoplasms of the pancreas: applications to diagnostic pathology. *Advances in Anatomic Pathology*, **2003**, 10, 125-34	5.1	10
69	Colchicine effect in a colonic hyperplastic polyp. A lesion mimicking serrated adenoma. *Archives of Pathology and Laboratory Medicine*, **2002**, 126, 615-7	5	10
68	Personalized Management of Pancreatic Ductal Adenocarcinoma Patients through Computational Modeling. *Cancer Research*, **2017**, 77, 3325-3335	10.1	9

67	The association between circulating high-sensitivity C-reactive protein concentration and pathologic measures of colonic inflammation. *Cancer Causes and Control*, **2014**, 25, 409-18	2.8	9
66	Cronkhite-Canada Syndrome: Gastric Involvement Diagnosed by MDCT. *Case Reports in Medicine*, **2009**, 2009, 148795	0.7	9
65	Homologous recombination deficiency (HRD): A biomarker for first-line (1L) platinum in advanced pancreatic ductal adenocarcinoma (PDAC).. *Journal of Clinical Oncology*, **2019**, 37, 4132-4132	2.2	8
64	Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes. *Journal of the National Cancer Institute*, **2021**, 113, 1194-1202	9.7	8
63	Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes. *Cancer*, **2019**, 125, 1441-1448	6.4	8
62	Are we systematically under-dosing patients with fluorouracil?. *Journal of Clinical Oncology*, **2015**, 33, e36-7	2.2	7
61	CpG island methylator phenotype and its association with malignancy in sporadic duodenal adenomas. *Epigenetics*, **2014**, 9, 738-46	5.7	7
60	Alterations of type II classical cadherin, cadherin-10 (CDH10), is associated with pancreatic ductal adenocarcinomas. *Genes Chromosomes and Cancer*, **2017**, 56, 427-435	5	6
59	An unusual genomic variant of pancreatic ductal adenocarcinoma with an indolent clinical course. *Journal of Physical Education and Sports Management*, **2017**, 3,	2.8	6
58	Transflip mutations produce deletions in pancreatic cancer. *Genes Chromosomes and Cancer*, **2015**, 54, 472-481	5	6
57	Local recurrences at the anastomotic area are clonally related to the primary tumor in sporadic colorectal carcinoma. *Oncotarget*, **2017**, 8, 42487-42494	3.3	6
56	Tumor diversity and evolution revealed through RADseq. *Oncotarget*, **2017**, 8, 41792-41805	3.3	6
55	Pancreatic cancers suppress negative feedback of glucose transport to reprogram chromatin for metastasis. *Nature Communications*, **2020**, 11, 4055	17.4	6
54	Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes. *Cancer*, **2021**, 127, 4393-4402	6.4	6
53	Simple mucinous cysts of the pancreas have heterogeneous somatic mutations. *Human Pathology*, **2020**, 101, 1-9	3.7	5
52	The mutational landscape of human somatic and germline cells		5
51	Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreatic adenocarcinoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 30670-30678	11.5	5
50	Pancreatic cancer prognosis is predicted by an ATAC-array technology for assessing chromatin accessibility. *Nature Communications*, **2021**, 12, 3044	17.4	5

49	Prospective assessment for pathogenic germline alterations (PGA) in pancreas cancer (PAC).. *Journal of Clinical Oncology*, **2017**, 35, 4102-4102	2.2	4
48	Cancer gene profiling in pancreatic cancer. *Methods in Molecular Biology*, **2010**, 576, 279-92	1.4	4
47	Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma. *BMC Cancer*, **2021**, 21, 385	4.8	4
46	Initial Whole-Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001. *Clinical Cancer Research* , **2021**, 27, 2111-2118	12.9	4
45	Personalized medicine in pancreatic cancer: prognosis and potential implications for therapy. *Journal of Gastrointestinal Surgery*, **2012**, 16, 1651-2	3.3	3
44	Young-onset pancreas cancer (PC) in patients less than or equal to 50 years old at Memorial Sloan Kettering (MSK): Descriptors, genomics, and outcomes.. *Journal of Clinical Oncology*, **2020**, 38, 774-774	2.2	3
43	Abstract 970: The mutational landscape of normal human endometrial epithelium **2019**,		3
42	The Pancreas **2010**, 891-904		3
41	Colloid Carcinomas of the Pancreas and Periampullary Region. *American Journal of Surgical Pathology*, **2002**, 26, 952-953	6.7	3
40	Inflammatory leptomeningeal cytokines mediate delayed COVID-19 encephalopathy **2020**,		3
39	The Genetic Basis of Transcriptional and Spatial Heterogeneity of Squamous Features in Pancreatic Ductal Adenocarcinoma		3
38	Cyst Fluid Analysis in Pancreatic Intraductal Papillary Mucinous Neoplasms. *Clinical Cancer Research*, **2016**, 22, 4966-4967	12.9	3
37	MYC levels regulate metastatic heterogeneity in pancreatic adenocarcinoma. *Cancer Discovery*, **2021**,	24.4	3
36	The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas. *Clinical Cancer Research*, **2021**, 27, 1516-1525	12.9	2
35	Abstract 4137: Clonal evolution defines the natural history of metastatic pancreatic cancer **2015**,		2
34	Plasma KRAS as a biomarker for pancreatic ductal adenocarcinoma (PDAC).. *Journal of Clinical Oncology*, **2018**, 36, 316-316	2.2	2
33	Cathepsin D protein levels in colorectal tumors: divergent expression patterns suggest complex regulation and function. *International Journal of Oncology*, **2004**, 24, 473-85	1	2
32	MITI minimum information guidelines for highly multiplexed tissue images.. *Nature Methods*, **2022**, 19, 262-267	21.6	2

31	StakeholdersPPerceptions and Information Needs Regarding Research Medical Donation. *Journal of Pain and Symptom Management*, **2019**, 58, 792-804.e6	4.8	1
30	The Hidden Beauty in Biomedical Imaging. *Journal of Visual Communication in Medicine*, **2015**, 38, 220-7	1.5	1
29	Cross-platform Comparison of Two Pancreatic Cancer Phenotypes. *Cancer Informatics*, **2010**, 9, 257-64	2.4	1
28	Immunohistochemistry and in situ hybridization in pancreatic neoplasia. *Methods in Molecular Medicine*, **2005**, 103, 67-88		1
27	The Science of Rapid Research Autopsy **2019**, 151-166		1
26	Reconstructing phylogenies of metastatic cancers		1
25	Evolutionary Dynamics of Non-Coding Regions in Pancreatic Ductal Adenocarcinoma		1
24	MYCcontrols metastatic heterogeneity in pancreatic cancer		1
23	Methylation-based Cell-free DNA Signature for Early Detection of Pancreatic Cancer. *Pancreas*, **2021**, 50, 1267-1273	2.6	0
22	Whole Genome Sequencing of Extramedullary Myeloma Autopsy Tumors Reveals a Genomic Portrait at Culmination of Clonal Convergence. *Blood*, **2018**, 132, 3169-3169	2.2	0
21	Blood-based screening for methylation changes in colorectal cancer patients using novel nanotechnologies.. *Journal of Clinical Oncology*, **2013**, 31, 384-384	2.2	0
20	Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts.. *Nature Communications*, **2022**, 13, 2144	17.4	0
19	Molecular pathology of pancreatic cancer and premalignant tumors **2017**, 139-149.e3		
18	Considerations for sequencing analyses of pancreatic cancer progression and metastasis. *Methods in Molecular Biology*, **2013**, 980, 121-9	1.4	
17	Initial Whole Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001. *Blood*, **2020**, 136, 50-51	2.2	
16	TCR Repertoires in Graft-Versus-Host-Disease (GVHD)-Target Tissues Reveals Tissue Specificity of the Alloimmune Response. *Blood*, **2020**, 136, 21-23	2.2	
15	Optimizing targeted agents development in pancreatic cancer: A fine-needle aspirate biopsy (FNAB) based ex vivo and in vivo assay. *Journal of Clinical Oncology*, **2006**, 24, 3002-3002	2.2	
14	Prospective analysis of somatic and germline genetic alterations in patients with ampullary carcinomas.. *Journal of Clinical Oncology*, **2018**, 36, 308-308	2.2	

13	Mytype: A Capture Based Sequencing Approach to Detect Somatic Mutations, Copy Number Changes and IGH Translocations in Multiple Myeloma. *Blood*, **2018**, 132, 5588-5588	2.2
12	StakeholdersPperceptions and information needs regarding research medical donation (RMD).. *Journal of Clinical Oncology*, **2018**, 36, 27-27	2.2
11	Pilot study of plasma KRAS as a prognostic biomarker in localized pancreas ductal adenocarcinoma (PDAC).. *Journal of Clinical Oncology*, **2019**, 37, 294-294	2.2
10	Association of pancreatic cancer stem cells with tumor stroma type.. *Journal of Clinical Oncology*, **2019**, 37, e15771-e15771	2.2
9	Detection of somatic mutations in fine needle aspirates of pancreatic cancer with next-generation sequencing.. *Journal of Clinical Oncology*, **2014**, 32, e15225-e15225	2.2
8	Genomic landscape of pancreatic adenocarcinoma: Does age matter?. *Journal of Clinical Oncology*, **2016**, 34, 250-250	2.2
7	Do pancreatic cancer (PDA) stem cell markers predict biologic behavior?. *Journal of Clinical Oncology*, **2016**, 34, 4112-4112	2.2
6	Whole Exome Sequencing from Nine Independent Sites of Extraosseous Disease in a Single Patient with Relapsed Multiple Myeloma Show That Extramedullary Disease Arise through a Combination of Branched and Parallel Evolution. *Blood*, **2016**, 128, 2090-2090	2.2
5	Do pancreas cancer stem cells play crucial role in survival outcome?. *Journal of Clinical Oncology*, **2017**, 35, e15721-e15721	2.2
4	The Genetics of Pancreatic Cancer Progression **2013**, 171-184	
3	Is successful resection following neoadjuvant radiation therapy for borderline resectable pancreatic cancer dependent on improved tumor-vessel relationships?. *Journal of Clinical Oncology*, **2013**, 31, 4057-4057	2.2
2	Association of ALDH-expressing cancer stem cells with survival in patients with resected pancreatic adenocarcinoma treated with adjuvant chemoradiation.. *Journal of Clinical Oncology*, **2014**, 32, 262-262	2.2
1	Evidence for reduced BRCA2 functional activity in Homo sapiens after divergence from the chimpanzee-human last common ancestor.. *Cell Reports*, **2022**, 39, 110771	10.6